Literature DB >> 21345147

Effects of Toll-like receptor signals in T-cell neoplasms.

Cori Morrison1, Maria R Baer, Dan P Zandberg, Amy Kimball, Eduardo Davila.   

Abstract

T-cell neoplasms have poor prognosis and few effective therapeutic options. Therefore, identification of factors in T-cell leukemia/lymphoma that are associated with cancer progression may represent novel therapeutic targets. Recent studies have highlighted a previously unappreciated role for the expression of Toll-like receptors (TLRs) on T cells and their effects on cell survival and proliferation. TLRs can bind exogenous molecules derived from pathogens as well as endogenous self-ligands released from damaged cells. Recent reports demonstrate that TLR engagement on primary mouse or human T cells enhances proliferation and/or cell survival. The mechanisms by which TLR stimulation on T cells influences these parameters and the different T-cell subsets that are affected by TLR stimulation are currently under investigation. Furthermore, neither the biological importance of stimulating TLRs on neoplastic T cells nor the prevalence of TLR expression in T-cell malignancies have yet to be characterized. Based on published reports and compelling preliminary data, we propose that the activation of the TLR-MyD88 signaling pathway in neoplastic T cells contributes to disease progression by reducing cell death and enhancing cell division. In this article, we present both theoretical arguments and experimental data in support of this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21345147      PMCID: PMC3463000          DOI: 10.2217/fon.10.185

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  111 in total

1.  Interleukin-1 receptor type 1 is a substrate for gamma-secretase-dependent regulated intramembrane proteolysis.

Authors:  Baukje M Elzinga; Ciara Twomey; James C Powell; Frances Harte; Justin V McCarthy
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

2.  Network model of survival signaling in large granular lymphocyte leukemia.

Authors:  Ranran Zhang; Mithun Vinod Shah; Jun Yang; Susan B Nyland; Xin Liu; Jong K Yun; Réka Albert; Thomas P Loughran
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

3.  Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity.

Authors:  Nicole Asprodites; Liqin Zheng; Degui Geng; Cruz Velasco-Gonzalez; Luis Sanchez-Perez; Eduardo Davila
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

Review 4.  Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases.

Authors:  Elaine Lin; Jane E Freedman; Lea M Beaulieu
Journal:  Cardiovasc Ther       Date:  2009       Impact factor: 3.023

5.  Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo.

Authors:  Mohan R Dasu; Andrea C Riosvelasco; Ishwarlal Jialal
Journal:  Atherosclerosis       Date:  2008-04-18       Impact factor: 5.162

6.  A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection.

Authors:  Michael Quigley; Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  Blood       Date:  2008-10-23       Impact factor: 22.113

7.  The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus.

Authors:  Yuan Zhao; Carl De Trez; Rachel Flynn; Carl F Ware; Michael Croft; Shahram Salek-Ardakani
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

8.  Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland.

Authors:  Enrique Sanchez-Lemus; Yuki Murakami; Ignacio M Larrayoz-Roldan; Armen J Moughamian; Jaroslav Pavel; Tsuyoshi Nishioku; Juan M Saavedra
Journal:  Endocrinology       Date:  2008-06-12       Impact factor: 4.736

9.  Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases.

Authors:  Ila Joshi; Lisa M Minter; Janice Telfer; Renée M Demarest; Anthony J Capobianco; Jon C Aster; Piotr Sicinski; Abdul Fauq; Todd E Golde; Barbara A Osborne
Journal:  Blood       Date:  2008-11-10       Impact factor: 22.113

10.  Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Authors:  Pedro J Real; Valeria Tosello; Teresa Palomero; Mireia Castillo; Eva Hernando; Elisa de Stanchina; Maria Luisa Sulis; Kelly Barnes; Catherine Sawai; Irene Homminga; Jules Meijerink; Iannis Aifantis; Giuseppe Basso; Carlos Cordon-Cardo; Walden Ai; Adolfo Ferrando
Journal:  Nat Med       Date:  2008-12-21       Impact factor: 53.440

View more
  4 in total

1.  Growth, metastasis, and expression of CCL2 and CCL5 by murine mammary carcinomas are dependent upon Myd88.

Authors:  Adetutu T Egunsola; Carolyn L Zawislak; Afua A Akuffo; Samantha A Chalmers; Jason C Ewer; Caroline M Vail; Jeffrey C Lombardo; Dana N Perez; Robert A Kurt
Journal:  Cell Immunol       Date:  2011-10-25       Impact factor: 4.868

Review 2.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

3.  T-cell activation and early gene response in dogs.

Authors:  Sally-Anne Mortlock; Jerry Wei; Peter Williamson
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 4.  Toll-like Receptors from the Perspective of Cancer Treatment.

Authors:  Nasir Javaid; Sangdun Choi
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.